A great deal has transpired in the antibiotics world since the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last convened one year ago. As researchers and antibiotic drug developers alike meet in Denver this week for the annual meeting, the focus is squarely on new product pipeline progress and whether those innovative products nearing the marketplace will be enough to alleviate the growing concern about multidrug resistance in virulent bacteria.